Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance

摘要: Summary Background The Global Project on Anti-Tuberculosis Drug Resistance has been gathering data since 1994. This study provides the latest extent of drug resistance worldwide. Methods Data for susceptibility were gathered from 90 726 patients in 83 countries and territories between 2002 2007. Standardised collection results enabled comparison both within countries. Where possible, HIV status to second-line drugs also obtained. Laboratory quality assured by Supranational Tuberculosis Reference Network. Findings median prevalence any new cases tuberculosis was 11·1% (IQR 7·0–22·3). multidrug ranged 0% eight 7% two provinces China, Northern Mariana Islands (although reporting only cases), 6·8% 22·3% nine former Soviet Union, including 19·4% Moldova Baku, Azerbaijan (median surveyed 1·6%, IQR 0·6–3·9). Trend analysis showed that 1994 2007, multidrug-resistant (MDR) increased substantially South Korea Tomsk Oblast Orel Oblast, Russia, but stable Estonia Latvia. MDR all decreased Hong Kong USA. 37 reported representative extensively drug-resistant (XDR) tuberculosis. Five countries, 25 or more XDR each, with among MDR-tuberculosis ranging 6·6% 23·7%. Interpretation remains a threat control China Union. are unavailable many especially Africa, emphasising need develop easier methods surveillance Funding Project: United States Agency International Development Eli Lilly Company. surveys: national programmes, Government Netherlands, Fund Fight AIDS, Malaria, Japan Cooperation Agency, Kreditanstalt fur Wiederaufbau.